THERANEXUS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.135 EUR | +1.34% |
|
+8.10% | +1.34% |
| Apr. 19 | Theranexus: share price rises following promising trial results | CF |
| Mar. 11 | Theranexus: CEO takes over as Chairman of the Board | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Theranexus is an innovative biopharmaceutical company that emerged from the French Atomic Energy Commission (CEA) and specializes in the treatment of neurological diseases and pioneer in the development of drug candidates targeting both neurons and glial cells.
Theranexus has a unique platform for the identification and characterization of innovative therapy drug candidates in rare neurological disorders and a first drug candidate in clinical development for Batten disease.
Calendar
2024-09-24
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.135
EUR
Average target price
4
EUR
Spread / Average Target
+252.42%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +1.34% | 9.31M | |
| -2.31% | 103B | |
| +0.56% | 95.71B | |
| +1.69% | 22.02B | |
| -17.37% | 20.9B | |
| -9.30% | 17.85B | |
| -41.01% | 16.21B | |
| -14.85% | 15.52B | |
| +3.21% | 13.86B | |
| +33.54% | 12.04B |
- Stock Market
- Equities
- ALTHX Stock
- News Theranexus
- Theranexus : Creates Drug Development JV; Stock Down4%
